Laurus Labs Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The strategic move will enable Laurus Labs to access 25.53 MW of renewable wind and solar energy, which aligns with regulatory requirements under Indian Electricity Laws and government policies for captive consumption of power. The investment is aimed at reducing electricity costs, ensuring a reliable green power supply, and obtaining carbon credits, thus contributing to the company's environmental, social, and governance (ESG) objectives.

Kurnool Renewables is engaged in the production of renewable energy, primarily from solar and wind sources. Laurus Labs' investment will support the development of the renewable power project, which will be used for captive consumption. This acquisition is expected to provide benefits such as reduced energy costs, enhanced energy security, and increased operational stability along with potential environmental advantages.

The equity shares will be subscribed at an issue price determined by Kurnool Renewables, with a total investment of up to Rs 35 crore. The payment will be made in cash in three stages: 30% within 30 days from the execution of agreements, 40% upon placing orders for major equipment, and the remaining 30% upon receipt of major equipment at the project site.

The acquisition does not fall within the purview of a related party transaction.

In addition, Laurus Labs' board has approved the re-appointment of V.V. Ravi Kumar as the Executive Director and Chief Financial Officer (CFO) of the company for a period of two years, effective from 1 April 2025, subject to shareholder approval.

V. V. Ravi Kumar is the executive director and chief financial officer of Laurus Labs Limited, bringing over three decades of rich experience, and especially two decades in Laurus itself, in finance, strategy, and corporate leadership. A qualified cost accountant from the Institute of Cost and Works Accountants of India, he plays a pivotal role in steering Laurus Labs toward sustainable growth and excellence. As a key leader at Laurus Labs, Mr. Ravi Kumar oversees critical business functions, including finance, information technology, mergers & acquisitions, strategic alliances, human resources, etc. He does not have any inter-se relationship with other directors of the company.

The board also approved the re-appointment of Dr. Satyanarayana Chava as executive director and CEO for five years, starting 1, April 2025, subject to shareholder approval.

Dr. Chava, the founder and CEO of Laurus Labs, has more than 30 years of experience in the pharmaceutical industry, with around 20 years at Laurus Labs. He holds a Ph.D. in chemistry from Andhra University and has been instrumental in positioning the company as a leader in both domestic and international markets.

Dr. Satyanarayana Chava is the father of Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava, executive directors of the company.

Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral and oncology drugs, cardiovascular, gastro, and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations and provides contract research and manufacturing services (CRAMS) to global pharma companies.

The company?s consolidated net profit soared 298.9% to Rs 92.30 crore in Q3 FY25 as against Rs 23.14 crore posted in Q3 FY24. Net sales jumped 18.4% YoY to Rs 1,415.05 crore in the quarter ended 31 December.

The counter shed 0.76% to Rs 613.50 on the BSE.

Powered by Capital Market - Live News

The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of an amount of Rs 83.30 crore in KRKA Pharma (KRKA), a joint venture of the Company.

Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of Rs 86.70 crore in KRKA. Thereby, maintaining the existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs.

The purpose of this investment is to acquire land and to meet initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company's strategic growth plans and long-term business objectives.

Powered by Capital Market - Live News

Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 564.2, up 3.43% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.3% on the day, quoting at 22369.85. The Sensex is at 73855.47, up 1.19%. Laurus Labs Ltd has dropped around 11.4% in last one month.

Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has dropped around 9.06% in last one month and is currently quoting at 19820.65, up 0.98% on the day. The volume in the stock stood at 18.59 lakh shares today, compared to the daily average of 27.02 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 565.1, up 3.1% on the day. Laurus Labs Ltd is up 37.39% in last one year as compared to a 0.46% fall in NIFTY and a 4.57% fall in the Nifty Pharma index.

The PE of the stock is 117.78 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of an amount of Rs 83.30 crore in KRKA Pharma (KRKA), a joint venture of the Company.

Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of Rs 86.70 crore in KRKA. Thereby, maintaining the existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs.

The purpose of this investment is to acquire land and to meet initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company's strategic growth plans and long-term business objectives.

Powered by Capital Market - Live News

Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 564.2, up 3.43% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.3% on the day, quoting at 22369.85. The Sensex is at 73855.47, up 1.19%. Laurus Labs Ltd has dropped around 11.4% in last one month.

Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has dropped around 9.06% in last one month and is currently quoting at 19820.65, up 0.98% on the day. The volume in the stock stood at 18.59 lakh shares today, compared to the daily average of 27.02 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 565.1, up 3.1% on the day. Laurus Labs Ltd is up 37.39% in last one year as compared to a 0.46% fall in NIFTY and a 4.57% fall in the Nifty Pharma index.

The PE of the stock is 117.78 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Laurus Labs Ltd is down for a fifth straight session today. The stock is quoting at Rs 546.75, down 9.03% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.87% on the day, quoting at 22830.85. The Sensex is at 75660.79, down 0.63%.Laurus Labs Ltd has lost around 1.82% in last one month.Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has eased around 5.47% in last one month and is currently quoting at 21427.1, down 3.06% on the day. The volume in the stock stood at 48.57 lakh shares today, compared to the daily average of 44.71 lakh shares in last one month.

The benchmark February futures contract for the stock is quoting at Rs 546.25, down 9.02% on the day. Laurus Labs Ltd jumped 39.28% in last one year as compared to a 4.2% rally in NIFTY and a 11.87% spurt in the Nifty Pharma index.

The PE of the stock is 129.77 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

The strategic move will enable Laurus Labs to access 25.53 MW of renewable wind and solar energy, which aligns with regulatory requirements under Indian Electricity Laws and government policies for captive consumption of power. The investment is aimed at reducing electricity costs, ensuring a reliable green power supply, and obtaining carbon credits, thus contributing to the company's environmental, social, and governance (ESG) objectives.

Kurnool Renewables is engaged in the production of renewable energy, primarily from solar and wind sources. Laurus Labs' investment will support the development of the renewable power project, which will be used for captive consumption. This acquisition is expected to provide benefits such as reduced energy costs, enhanced energy security, and increased operational stability along with potential environmental advantages.

The equity shares will be subscribed at an issue price determined by Kurnool Renewables, with a total investment of up to Rs 35 crore. The payment will be made in cash in three stages: 30% within 30 days from the execution of agreements, 40% upon placing orders for major equipment, and the remaining 30% upon receipt of major equipment at the project site.

The acquisition does not fall within the purview of a related party transaction.

In addition, Laurus Labs' board has approved the re-appointment of V.V. Ravi Kumar as the Executive Director and Chief Financial Officer (CFO) of the company for a period of two years, effective from 1 April 2025, subject to shareholder approval.

V. V. Ravi Kumar is the executive director and chief financial officer of Laurus Labs Limited, bringing over three decades of rich experience, and especially two decades in Laurus itself, in finance, strategy, and corporate leadership. A qualified cost accountant from the Institute of Cost and Works Accountants of India, he plays a pivotal role in steering Laurus Labs toward sustainable growth and excellence. As a key leader at Laurus Labs, Mr. Ravi Kumar oversees critical business functions, including finance, information technology, mergers & acquisitions, strategic alliances, human resources, etc. He does not have any inter-se relationship with other directors of the company.

The board also approved the re-appointment of Dr. Satyanarayana Chava as executive director and CEO for five years, starting 1, April 2025, subject to shareholder approval.

Dr. Chava, the founder and CEO of Laurus Labs, has more than 30 years of experience in the pharmaceutical industry, with around 20 years at Laurus Labs. He holds a Ph.D. in chemistry from Andhra University and has been instrumental in positioning the company as a leader in both domestic and international markets.

Dr. Satyanarayana Chava is the father of Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava, executive directors of the company.

Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral and oncology drugs, cardiovascular, gastro, and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations and provides contract research and manufacturing services (CRAMS) to global pharma companies.

The company?s consolidated net profit soared 298.9% to Rs 92.30 crore in Q3 FY25 as against Rs 23.14 crore posted in Q3 FY24. Net sales jumped 18.4% YoY to Rs 1,415.05 crore in the quarter ended 31 December.

The counter shed 0.76% to Rs 613.50 on the BSE.

Powered by Capital Market - Live News

The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of an amount of Rs 83.30 crore in KRKA Pharma (KRKA), a joint venture of the Company.

Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of Rs 86.70 crore in KRKA. Thereby, maintaining the existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs.

The purpose of this investment is to acquire land and to meet initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company's strategic growth plans and long-term business objectives.

Powered by Capital Market - Live News

Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 564.2, up 3.43% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.3% on the day, quoting at 22369.85. The Sensex is at 73855.47, up 1.19%. Laurus Labs Ltd has dropped around 11.4% in last one month.

Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has dropped around 9.06% in last one month and is currently quoting at 19820.65, up 0.98% on the day. The volume in the stock stood at 18.59 lakh shares today, compared to the daily average of 27.02 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 565.1, up 3.1% on the day. Laurus Labs Ltd is up 37.39% in last one year as compared to a 0.46% fall in NIFTY and a 4.57% fall in the Nifty Pharma index.

The PE of the stock is 117.78 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of an amount of Rs 83.30 crore in KRKA Pharma (KRKA), a joint venture of the Company.

Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of Rs 86.70 crore in KRKA. Thereby, maintaining the existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs.

The purpose of this investment is to acquire land and to meet initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company's strategic growth plans and long-term business objectives.

Powered by Capital Market - Live News

Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 564.2, up 3.43% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.3% on the day, quoting at 22369.85. The Sensex is at 73855.47, up 1.19%. Laurus Labs Ltd has dropped around 11.4% in last one month.

Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has dropped around 9.06% in last one month and is currently quoting at 19820.65, up 0.98% on the day. The volume in the stock stood at 18.59 lakh shares today, compared to the daily average of 27.02 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 565.1, up 3.1% on the day. Laurus Labs Ltd is up 37.39% in last one year as compared to a 0.46% fall in NIFTY and a 4.57% fall in the Nifty Pharma index.

The PE of the stock is 117.78 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Laurus Labs Ltd is down for a fifth straight session today. The stock is quoting at Rs 546.75, down 9.03% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.87% on the day, quoting at 22830.85. The Sensex is at 75660.79, down 0.63%.Laurus Labs Ltd has lost around 1.82% in last one month.Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has eased around 5.47% in last one month and is currently quoting at 21427.1, down 3.06% on the day. The volume in the stock stood at 48.57 lakh shares today, compared to the daily average of 44.71 lakh shares in last one month.

The benchmark February futures contract for the stock is quoting at Rs 546.25, down 9.02% on the day. Laurus Labs Ltd jumped 39.28% in last one year as compared to a 4.2% rally in NIFTY and a 11.87% spurt in the Nifty Pharma index.

The PE of the stock is 129.77 based on TTM earnings ending December 24.

Powered by Capital Market - Live News